Moderna
MRNA
Market cap $13.1B

34.06 USD

+0.30

0.89%

At close Jan 17, 4:00 PM EST

After hours

35.60

+1.54

4.52%

1 day

0.89%

5 days

2.28%

1 month

-16.44%

3 months

-37.87%

6 months

-72.55%

Year to date

-18.90%

1 year

-66.06%

5 years

65.18%

10 years

83.12%

About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Employees: 5,600

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,823 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.61% less ownership

Funds ownership: 70.2% [Q2] → 67.59% (-2.61%) [Q3]

18% less funds holding

Funds holding: 929 [Q2] → 765 (-164) [Q3]

21% less repeat investments, than reductions

Existing positions increased: 250 | Existing positions reduced: 316

36% less call options, than puts

Call options by funds: $926M | Put options by funds: $1.46B

46% less capital invested

Capital invested by funds: $32B [Q2] → $17.3B (-$14.6B) [Q3]

46% less funds holding in top 10

Funds holding in top 10: 13 [Q2] → 7 (-6) [Q3]

71% less first-time investments, than exits

New positions opened: 62 | Existing positions closed: 213

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$38

12%

upside

Avg. target

$62

83%

upside

High target

$111

226%

upside

8 analyst ratings

4 positive

50%

1 neutral

13%

3 negative

38%

Morgan Stanley Matthew Harrison 35% 1-year accuracy 6 / 17 met price target	12%upside $38	Equal-Weight Maintained	15 Jan 2025
UBS Eliana Merle 16% 1-year accuracy 3 / 19 met price target	182%upside $96	Buy Maintained	8 Jan 2025
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target	20%upside $41	Underperform Reinstated	10 Dec 2024
JP Morgan Jessica Fye 47% 1-year accuracy 18 / 38 met price target	32%upside $45	Underweight Maintained	26 Nov 2024
Piper Sandler Edward Tenthoff 18% 1-year accuracy 8 / 45 met price target	103%upside $69	Overweight Reiterated	18 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 65 articles about MRNA published over the past 30 days

Zacks Investment Research

Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab

MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.

Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab

Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028. Merck stands to lose $62 billion over four years following the loss of exclusivity on KEYTRUDA, making Moderna's $13 billion market cap a bargain.

Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership

The Motley Fool

Is Moderna Stock a Buy?

Share prices of Moderna (MRNA 0.89%) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on messenger RNA (mRNA), has struggled to manage weak sales of COVID-19 vaccine and sluggish market adoption of its new shot for respiratory syncytial virus (RSV).

Is Moderna Stock a Buy?

The Motley Fool

These Were the 5 Worst-Performing Stocks in the S&P 500 in 2024

Returning 25% in 2024, the S&P 500 delivered a record-breaking year for stock market investors. A resilient global economy coupled with interest rate cuts by the Federal Reserve continues to fuel optimism toward a strong outlook.

These Were the 5 Worst-Performing Stocks in the S&P 500 in 2024

CNBC Television

Moderna is a 'trade' on Bird Flu vaccine pop, says Mizuho's Jared Holz

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Moderna is a 'trade' on Bird Flu vaccine pop, says Mizuho's Jared Holz

Moderna Gets $590 Million of Federal Funding For Influenza Vaccines

The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the company said

Moderna Gets $590 Million of Federal Funding For Influenza Vaccines

Moderna Announces Updates on Pandemic Influenza Program

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR).

Moderna Announces Updates on Pandemic Influenza Program

US awards Moderna $590 million for bird flu vaccine development

The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.

US awards Moderna $590 million for bird flu vaccine development

Zacks Investment Research

How to Play Moderna Stock After the Recent Sales Guidance Cut

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

How to Play Moderna Stock After the Recent Sales Guidance Cut

Zacks Investment Research

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

See News Rankings

Charts implemented using Lightweight Charts™